Grit Biotherapeutics Announces Three Upcoming Presentations at the 2026 American Association for Cancer Research Annual Meeting

Beijing and Shanghai, China, April 2, 2026 – Beijing Grit Biotherapeutics Co., Ltd. (“Grit Bio”), a clinical stage biotechnology company pioneering novel immunotherapies, is pleased to announce the company will be presenting three posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, taking place at San Diego Convention Center in California, from April 17 to 22, 2026.

The three posters will feature 1) updated clinical data and TCR clonal dynamics of GT201, a cytokine-armored tumor infiltrating lymphocyte (“TIL”) product expressing membrane-bound IL-15 (mbIL-15); 2) the development, preclinical data, and preliminary clinical results of GT801, a novel anti-CD19 in vivo CAR-T candidate; and 3) preliminary safety and efficacy data of GT719, an allogeneic anti-CD19 CAR-iNKT therapy generated through in vitro differentiation of cord blood-derived CD34+ hematopoietic stem cells. Details of the presentations are as follows:

Title: Armored TIL GT201 induces potent tumor-specific TCR expansion and durable antitumor responses in advanced solid tumor
Session Category: Clinical Research
Session Title: Biomarkers Predictive of Therapeutic Benefit 5
Session Start: 4/21/2026 9:00:00 AM local time
Session End: 4/21/2026 12:00:00 PM local time
Location: Poster Section 42
Poster Board Number: 23
Poster Number: 5257

Title: In vivo CAR-T T-LNP system (GT801) drives potent B cell depletion and clinical feasibility in hematologic and autoimmune conditions
Session Category: Immunology
Session Title: Alternative Cell Type and in Situ Cell Therapies
Session Start: 4/19/2026 2:00:00 PM local time
Session End: 4/19/2026 5:00:00 PM local time
Location: Poster Section 7
Poster Board Number: 22
Poster Number: 148

Title: Stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy GT719 for relapsed/refractory B cell malignancies
Session Category: Clinical Research
Session Title: Adoptive Cell Therapy 1
Session Start Time: 4/20/2026 2:00:00 PM local time
Session End Time: 4/20/2026 5:00:00 PM local time
Location: Poster Section 40
Poster Board Number: 27
Presentation Number: 3725

"We are delighted to share the latest progress and data of GT201, GT801, and GT719, which collectively demonstrate Grit Bio’s comprehensive expertise in cell therapies,” said Dr. Yarong Liu, Founder and CEO of Grit Bio. “The results are one more concrete step validating our technology platforms in TIL, allogeneic cell therapies and in vivo CAR-T. We will further leverage our leadership in cell therapies to add novel treatment options for patients with significant unmet medical need."

About Grit Bio
Founded in 2019, we are an R&D-driven, late-stage biopharmaceutical company developing next-generation immunotherapies for patients with cancer and autoimmune diseases worldwide. Leveraging our insights in immunotherapies, established R&D and technology platforms, and comprehensive manufacturing capabilities, we have built a diversified pipeline of seven product candidates in both the United States and China to address unmet clinical needs. GT101, a proprietary injectable developed by Grit Bio, is the first TIL therapy that entered registrational clinical trial in China and is currently in pivotal Phase II clinical study. Grit Bio's GT201 injectable, the first TIL therapy with membrane-bound IL-15 complex, has cleared IND in both US and China and initiated Phase I clinical study. Additionally, the company has a highly innovative project matrix, including autologous TIL enhanced with dual gene knock-outs, mRNA-based neoantigen cancer vaccine, the first universal CAR-iNKT therapy generated through differentiation of stem cells, and next-generation in vivo CAR-T.

We are committed to addressing the critical limitations of current treatments for cancer and autoimmune diseases and reshaping the therapeutic landscape of immunotherapies by driving three fundamental shifts: from hematologic malignancies to solid tumors, from autologous therapies to off-the-shelf allogeneic therapies, and from ex vivo to in vivo engineering. Our ultimate goal is to deliver therapies that are impactful, affordable, and accessible to patients worldwide. For further information, please visit: www.grit-bio.com